Perrigo (PRGO)
(Delayed Data from NYSE)
$26.94 USD
-0.06 (-0.22%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $26.94 0.00 (0.00%) 5:26 PM ET
3-Hold of 5 3
A Value D Growth B Momentum B VGM
Brokerage Reports
0 items in cart
Perrigo Company plc [PRGO]
Reports for Purchase
Showing records 321 - 340 ( 365 total )
Company: Perrigo Company plc
Industry: Medical - Products
Company: Perrigo Company plc
Industry: Medical - Products
Company: Perrigo Company plc
Industry: Medical - Products
Company: Perrigo Company plc
Industry: Medical - Products
Company: Perrigo Company plc
Industry: Medical - Products
Our Deep Dive into F2014 EPS and Some Large Underappreciated Product Opportunities Keep Us Positive
Provider: Guggenheim Securities LLC
Analyst: CHEN L
Company: Perrigo Company plc
Industry: Medical - Products
Company: Perrigo Company plc
Industry: Medical - Products
Company: Perrigo Company plc
Industry: Medical - Products
Company: Perrigo Company plc
Industry: Medical - Products
F2013 and F2014 Upward Earnings Revisions Continue with the Acquisition of Rosemont
Provider: Guggenheim Securities LLC
Analyst: CHEN L
Company: Perrigo Company plc
Industry: Medical - Products
Company: Perrigo Company plc
Industry: Medical - Products
F2Q13 Quality Beat and Velcera Acquisition Underscore Long-Term Growth Prospects Intact
Provider: Guggenheim Securities LLC
Analyst: CHEN L
Company: Perrigo Company plc
Industry: Medical - Products
Company: Perrigo Company plc
Industry: Medical - Products
Cutting Rating to 2*/Above Avg.--Less Consistent Sales Performance Warrants Lower P/E Target
Provider: CARIS & COMPANY
Company: Perrigo Company plc
Industry: Medical - Products
Company: Perrigo Company plc
Industry: Medical - Products
Company: Perrigo Company plc
Industry: Medical - Products
Gearing Up for Additional Growth Raising Price Target to $106
Provider: CLAL FINANCE
Analyst: KREIZMAN J
Company: Perrigo Company plc
Industry: Medical - Products
Initiating Coverage
Provider: Guggenheim Securities LLC
Company: Perrigo Company plc
Industry: Medical - Products
Stock Should Trend Higher As Investors Better Grasp the Sergeant''s Deal--Boosting Rating and Price Target to $136
Provider: CARIS & COMPANY
Company: Perrigo Company plc
Industry: Medical - Products
Company: Perrigo Company plc
Industry: Medical - Products
Mid-Teens Organic Op. Profit Growth Projected for FY13 and FY14
Provider: CARIS & COMPANY